HighTower Advisors’s IN8bio INAB Stock Holding History

HighTower Advisors’s Portfolio INAB Stock Details INAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-333	Closed	-$1.66K	–	3864
2025 Q1	$1.66K	Hold	333	–	–	﹤0.01%	3632
2024 Q4	$2.57K	Hold	333	–	–	﹤0.01%	3669
2024 Q3	$3K	Hold	333	–	–	﹤0.01%	3617
2024 Q2	$8K	Buy	+333	New	+$10.7K	﹤0.01%	3460
2024 Q1	–	Sell	-333	Closed	-$14K	–	3818
2023 Q4	$14K	Hold	333	–	–	﹤0.01%	3419
2023 Q3	$10K	Hold	333	–	–	﹤0.01%	3385
2023 Q2	$15K	Hold	333	–	–	﹤0.01%	3272
2023 Q1	$13K	Hold	333	–	–	﹤0.01%	3185
2022 Q4	$23K	Sell	333 -139	-29%	-$7.78K	﹤0.01%	3119
2022 Q3	$28K	Buy	+472	New	+$31.7K	﹤0.01%	2945
2022 Q2	–	Sell	-472	Closed	-$47K	–	3383
2022 Q1	$47K	Buy	472 +139	+42%	+$15.6K	﹤0.01%	3080
2021 Q4	$44K	Buy	+333	New	+$65.7K	﹤0.01%	3036

Other funds holding INAB

BCM

BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northwestern Mutual Wealth Management Milwaukee, Wisconsin $162B AUM 16.35% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

HighTower Advisors's INAB Position: Q2 2025 in Review

HighTower Advisors sold out of IN8bio (INAB) in Q2 2025, closing a stake of 333 shares — an estimated $1.66K sold.

HighTower Advisors first reported a position in INAB in Q4 2021 and held it in 12 quarters. The position peaked at $47K in Q1 2022. 12 funds tracked by Wall St. Rank hold INAB as of Q2 2025.

HighTower Advisors reported no remaining IN8bio position as of Q2 2025 after selling out during the quarter.
HighTower Advisors sold 333 IN8bio shares in Q2 2025, an estimated $1.66K.
HighTower Advisors first reported a position in IN8bio in Q4 2021 and held it in 12 quarters.
HighTower Advisors's IN8bio position peaked at $47K in Q1 2022.
12 funds tracked by Wall St. Rank held IN8bio as of Q2 2025.

Based on HighTower Advisors's 13F filing for Q2 2025, filed 11 Aug 2025.